Organ-on-a-Chip Technology and Global Multi-Omics: Current Applications and Future Directions

Abstract

Biomedical research models are undergoing continuous evolution, while conventional models (two-dimensional/ three-dimensional cultures and animal studies) face limitations in physiological relevance and ethical constraints. Against this backdrop, the integration of organ-on-a-chip (OoC) technology with multi-omics methodologies is driving a profound paradigm shift in the field. OoC platforms utilize microfluidic technology to construct biomimetic three-dimensional microenvironments capable of highly simulating human physiological and pathological states, while multi-omics technologies (e.g., proteomics, transcriptomics, and metabolomics) provide systematic molecular profiling capabilities. The integration of these two approaches enables multi-scale mechanistic analysis from molecular networks to the tissue level, significantly enhancing their potential in drug development and personalized medicine strategies. This article systematically reviews the research progress and existing challenges in this interdisciplinary field, with a focus on: (1) The developmental trajectory of OoC platforms from two-dimensional to biomimetic three-dimensional systems; (2) mechanistic insights revealed by the integration of multi-omics and OoC technology in modeling disease processes; and (3) key issues in the standardization and clinical translation of OoC technology. Finally, the paper proposes a development roadmap for constructing next-generation disease models, aiming to provide a theoretical framework and strategic guidance for the establishment of standardized systems and clinical translation pathways in this field.

Keywords

disease mechanism / drug discovery / multi-omics technology / organ-on-a-chip

References

[1] D. S. Dhanjal, P. Sharma, M. Mehta, et al., “Concepts of Advanced Therapeutic Delivery Systems for the Management of Remodeling and Inflammation in Airway Diseases,” Future Medicinal Chemistry 14, no. 4 (2022): 271–288.

[2] T.-M. Kim, K. R. Paudel, and D.-W. Kim, “Eriobotrya japonica Leaf Extract Attenuates Airway Inflammation in Ovalbumin-Induced Mice Model of Asthma,” Journal of Ethnopharmacology 253 (2020): 112082.

[3] J. Shrestha, S. Razavi Bazaz, H. Aboulkheyr Es, et al., “Lung-on-a-Chip: The Future of Respiratory Disease Models and Pharmacological Studies,” Critical Reviews in Biotechnology 40, no. 2 (2020): 213–230.

[4] M. J. Waring, J. Arrowsmith, A. R. Leach, et al., “An Analysis of the Attrition of Drug Candidates From Four Major Pharmaceutical Companies,” Nature Reviews Drug Discovery 14, no. 7 (2015): 475–486.

[5] J. Shrestha, S. T. Ryan, O. Mills, et al., “A 3D-Printed Microfluidic Platform for Simulating the Effects of CPAP on the Nasal Epithelium,” Biofabrication 13, no. 3 (2021): 035028.

[6] I. Francis, J. Shrestha, K. R. Paudel, et al., “Recent Advances in Lung-on-a-Chip Models,” Drug Discovery Today 27, no. 9 (2022): 2593–2602.

[7] M. De Jong and T. Maina, “Of Mice and Humans: Are They the Same?–Implications in Cancer Translational Research,” Journal of Nuclear Medicine 51, no. 4 (2010): 501–504.

[8] M. Zanoni, F. Piccinini, C. Arienti, et al., “3D Tumor Spheroid Models for in Vitro Therapeutic Screening: A Systematic Approach to Enhance the Biological Relevance of Data Obtained,” Scientific Reports 6, no. 1 (2016): 19103.

[9] G.-B. Liang and Z.-H. He, “Animal Models of Emphysema,” Chinese Medical Journal 132, no. 20 (2019): 2465–2475.

[10] H. Aydogmus, M. Hu, L. Ivancevic, et al., “An Organ-on-Chip Device With Integrated Charge Sensors and Recording Microelectrodes,” Scientific Reports 13, no. 1 (2023): 8062.

[11] R. Mittal, F. W. Woo, C. S. Castro, et al., “Organ-on-Chip Models: Implications in Drug Discovery and Clinical Applications,” Journal of Cellular Physiology 234, no. 6 (2018): 8352–8380.

[12] D. Huh, H. J. Kim, J. P. Fraser, et al., “Microfabrication of Human Organs-on-Chips,” Nature Protocols 8, no. 11 (2013): 2135–2157.

[13] A. Varone, J. K. Nguyen, L. Leng, et al., “A Novel Organ-Chip System Emulates Three-Dimensional Architecture of the Human Epithelia and the Mechanical Forces Acting on It,” Biomaterials 275 (2021): 120957.

[14] H. Bai and D. E. Ingber, “What Can an Organ-on-a-Chip Teach Us about Human Lung Pathophysiology?,” Physiology 37, no. 5 (2022): 242–252.

[15] S. N. Bhatia and D. E. Ingber, “Microfluidic Organs-on-Chips,” Nature Biotechnology 32, no. 8 (2014): 760–772.

[16] A. A. Kızılkurtlu, T. Polat, G. B. Aydın, et al., “Lung on a Chip for Drug Screening and Design,” Current Pharmaceutical Design 24, no. 45 (2019): 5386–5396.

[17] P. C. Chandrasekera, “Of Rodents and Men: Species-Specific Glucose Regulation and Type 2 Diabetes Research,” Altex 31 (2014): 157–176.

[18] Q. Dasgupta, A. Jiang, A. M. Wen, et al., “A Human Lung Alveolus-on-a-Chip Model of Acute Radiation-Induced Lung Injury,” Nature Communications 14, no. 1 (2023): 6506.

[19] J. Zhao, F. Shen, S. Sheng, et al., “Cartilage-on-Chip for Osteoarthritis Drug Screening,” Organoid Research 1, no. 1 (2025): 8461.

[20] Y. Man, Y. Liu, Q. Chen, et al., “Organoids-On-a-Chip for Personalized Precision Medicine,” Advanced Healthcare Materials 13, no. 30 (2024): e2401843.

[21] S. Zhang, H. Shen, W. Wei, et al., “Patient-Derived Tumor Organoids-Guided Adjuvant Chemotherapy After Surgical Resection of Intrahepatic Cholangiocarcinoma: A Multicenter and Retrospective Study,” Organoid Research 1, no. 1 (2025): 8571.

[22] Z. Li, D. Yu, C. Zhou, et al., “Engineering Vascularised Organoid-on-a-Chip: Strategies, Advances and Future Perspectives,” BMT 5, no. 1 (2024): 21–32.

[23] H. H. Jun Li and L. Qian, “Cardiac Organ Chip: Advances in Construction and Application,” Biomaterials Translational 5, no. 4 (2024): 411–424.

[24] H. Tang, Y. Abouleila, L. Si, et al., “Human Organs-on-Chips for Virology,” Trends in Microbiology 28, no. 11 (2020): 934–946.

[25] L. Si, H. Bai, M. Rodas, et al., “A Human-Airway-on-a-Chip for the Rapid Identification of Candidate Antiviral Therapeutics and Prophylactics,” Nature Biomedical Engineering 5, no. 8 (2021): 815–829.

[26] Q. Huang, T. Yang, Y. Song, et al., “A Three-Dimensional (3D) Liver-Kidney on a Chip With a Biomimicking Circulating System for Drug Safety Evaluation,” Lab on a Chip 24, no. 6 (2024): 1715–1726.

[27] B. S. Elci, M. Nikolaev, S. Rezakhani, et al., “Bioengineered Tubular Biliary Organoids,” Advanced Healthcare Materials 13, no. 8 (2024): e2302912.

[28] H.-T. Nguyen, S.-L. Rissanen, M. Peltokangas, et al., “Highly Scalable and Standardized Organ-on-chip Platform With TEER for Biological Barrier Modeling,” Tissue Barriers 12, no. 4 (2024): 2315702.

[29] V. Paloschi, M. Sabater-Lleal, H. Middelkamp, et al., “Organ-on-a-Chip Technology: A Novel Approach to Investigate Cardiovascular Diseases,” Cardiovascular Research 117, no. 14 (2021): 2742–2754.

[30] R. Janssen, J. W. M. de Kleer, B. Heming, et al., “Food Allergen Sensitization on a Chip: The Gut–Immune–Skin Axis,” Trends in Biotechnology 42, no. 1 (2024): 119–134.

[31] E. Papadaki, I. Kakkos, P. Vlamos, et al., “Recent Web Platforms for Multi-Omics Integration Unlocking Biological Complexity,” Applied Sciences 15, no. 1 (2024): 329.

[32] Y. Hasin, M. Seldin, and A. Lusis, “Multi-Omics Approaches to Disease,” Genome Biology 18, no. 1 (2017): 83.

[33] Q. Han, W. Bing, Y. Di, et al., “Kinsenoside Screening With a Microfluidic Chip Attenuates Gouty Arthritis Through Inactivating NF-κB Signaling in Macrophages and Protecting Endothelial Cells,” Cell Death & Disease 7, no. 9 (2016): e2350.

[34] C. Li, Y.-D. Sun, G.-Y. Yu, et al., “Integrated Omics of Metastatic Colorectal Cancer,” Cancer Cell 38, no. 5 (2020): 734–747.

[35] C. D. Gutierrez Reyes, G. Alejo-Jacuinde, B. Perez Sanchez, et al., “Multi Omics Applications in Biological Systems,” Current Issues in Molecular Biology 46, no. 6 (2024): 5777–5793.

[36] Y. Tao, S. Xing, S. Zuo, et al., “Cell-Free Multi-Omics Analysis Reveals Potential Biomarkers in Gastrointestinal Cancer Patients' Blood,” Cell Reports Medicine 4, no. 11 (2023): 101281.

[37] J. Fu, V. R. T. Zanotelli, C. Howald, et al., “A Multi-Omics Framework for Decoding Disease Mechanisms: Insights from Methylmalonic Aciduria,” Molecular & Cellular Proteomics 24, no. 7 (2025): 100998.

[38] S. Sebastian, S. Roy, and J. Kalita, “Network-Based Analysis of Alzheimer's Disease Genes Using Multi-Omics Network Integration With Graph Diffusion,” Journal of Biomedical Informatics 164 (2025): 104797.

[39] J. Morrone, S. Coakley, S. Blacker, et al., “Neural Indicators of Sleep Loss and Sleep Propensity in Male Military Trainees: Insights From Dry-Electrode EEG-An Exploratory Study,” Physiological Reports 13, no. 7 (2025): e70301.

[40] X. Xu, S. Cheung, X. Jia, et al., “Trends in Organ-on-a-Chip for Pharmacological Analysis,” TrAC Trends in Analytical Chemistry 180 (2024): 117905.

[41] U. M. N. Cao, Y. Zhang, J. Chen, et al., “Microfluidic Organ-on-a-Chip: A Guide to Biomaterial Choice and Fabrication,” International Journal of Molecular Sciences 24, no. 4 (2023): 3232.

[42] S. Musah, R. Bhattacharya, and J. Himmelfarb, “Kidney Disease Modeling With Organoids and Organs-on-Chips,” Annual Review of Biomedical Engineering 26, no. 1 (2024): 383–414.

[43] L. Wang, S. L. Liu, and N. Wu, “Application and Development of Organ-on-a-Chip Technology in Cancer Therapy,” Frontiers in Oncology 15 (2025): 1643230.

[44] Y. Sun, J. Liu, L. Zhu, et al., “Treatment Response to Oncolytic Virus in Patient-Derived Breast Cancer and Hypopharyngeal Cancer Organoids: Evaluation via a Microfluidics Organ-on-a-Chip System,” Bioengineering 12, no. 2 (2025): 146.

[45] X. Zeng, Q. Ma, X.-K. Li, et al., “Patient-Derived Organoids of Lung Cancer Based on Organoids-on-a-Chip: Enhancing Clinical and Translational Applications,” Frontiers in Bioengineering and Biotechnology 11 (2023): 1205157.

[46] L. Zheng, H. Dong, W. Zhao, et al., “An Air-Liquid Interface Organ-Level Lung Microfluidics Platform for Analysis on Molecular Mechanisms of Cytotoxicity Induced by Cancer-Causing Fine Particles,” ACS Sensors 4, no. 4 (2019): 907–917.

[47] M. Xu, Y. Wang, W. Duan, et al., “Proteomic Reveals Reasons for Acquired Drug Resistance in Lung Cancer Derived Brain Metastasis Based on a Newly Established Multi-Organ Microfluidic Chip Model,” Frontiers in Bioengineering and Biotechnology 8 (2020): 612091.

[48] M. T. Kastlmeier, E. M. Guenther, T. Stoeger, et al., “Lung Organoids for Hazard Assessment of Nanomaterials,” International Journal of Molecular Sciences 23, no. 24 (2022): 15666.

[49] A. Skardal, S. V. Murphy, M. Devarasetty, et al., “Multi-Tissue Interactions in an Integrated Three-Tissue Organ-on-a-Chip Platform,” Scientific Reports 7, no. 1 (2017): 8837.

[50] A. Krakos, A. Cieślak, E. Hartel, et al., “3D Bio-Printed Hydrogel Inks Promoting Lung Cancer Cell Growth in a Lab-on-Chip Culturing Platform,” Microchimica Acta 190, no. 9 (2023): 349.

[51] N. Farhang Doost and S. K. Srivastava, “A Comprehensive Review of Organ-on-a-Chip Technology and Its Applications,” Biosensors 14, no. 5 (2024): 225.

[52] L. P. Ferreira, V. M. Gaspar, and J. F. Mano, “Design of Spherically Structured 3D in Vitro Tumor Models -Advances and Prospects,” Acta Biomaterialia 75 (2018): 11–34.

[53] A. Moldasheva, L. Bakyt, D. Bulanin, et al., “The Impact of Cellular Environment on in Vitro Drug Screening,” Future Science OA 9, no. 9 (2023): FSO900.

[54] J. C. Fontoura, C. Viezzer, F. G. Santos, et al., “Comparison of 2D and 3D Cell Culture Models for Cell Growth, Gene Expression and Drug Resistance,” Materials Science and Engineering: C 107 (2020): 110264.

[55] Y. Park, K. M. Huh, and S.-W. Kang, “Applications of Biomaterials in 3D Cell Culture and Contributions of 3D Cell Culture to Drug Development and Basic Biomedical Research,” International Journal of Molecular Sciences 22, no. 5 (2021): 2491.

[56] K. A. Kilian, B. Bugarija, B. T. Lahn, et al., “Geometric Cues for Directing the Differentiation of Mesenchymal Stem Cells,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 11 (2010): 4872–4877.

[57] C. M. Nelson and M. J. Bissell, “Of Extracellular Matrix, Scaffolds, and Signaling: Tissue Architecture Regulates Development, Homeostasis, and Cancer,” Annual Review of Cell and Developmental Biology 22, no. 1 (2006): 287–309.

[58] A. Birgersdotter, R. Sandberg, and I. Ernberg, “Gene Expression Perturbation in Vitro-A Growing Case for Three-dimensional (3D) Culture Systems,” Seminars in Cancer Biology 15, no. 5 (2005): 405–412.

[59] K. Han, S. E. Pierce, A. Li, et al., “CRISPR Screens in Cancer Spheroids Identify 3D Growth-Specific Vulnerabilities,” Nature 580, no. 7801 (2020): 136–141.

[60] R. Edmondson, J. J. Broglie, A. F. Adcock, et al., “Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors,” ASSAY and Drug Development Technologies 12, no. 4 (2014): 207–218.

[61] M. A. Lancaster and J. A. Knoblich, “Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies,” Science 345 (2014): 6194.

[62] W. H. Abuwatfa, W. G. Pitt, and G. A. Husseini, “Scaffold-Based 3D Cell Culture Models in Cancer Research,” Journal of Biomedical Science 31, no. 1 (2024): 7.

[63] I. Flörkemeier, L. K. Antons, J. P. Weimer, et al., “Multicellular Ovarian Cancer Spheroids: Novel 3D Model to Mimic Tumour Complexity,” Scientific Reports 14, no. 1 (2024): 23526.

[64] C.-R. Yang, C.-T. Liang, S.-C. Tsai, et al., “A Novel 3D Culture Scaffold to Shorten Development Time for Multicellular Tumor Spheroids,” International Journal of Molecular Sciences 23, no. 22 (2022): 13962.

[65] O. Habanjar, M. Diab-Assaf, F. Caldefie-Chezet, et al., “3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages,” International Journal of Molecular Sciences 22, no. 22 (2021): 12200.

[66] T. S. Biju, V. V. Priya, and A. P. Francis, “Role of Three-Dimensional Cell Culture in Therapeutics and Diagnostics: An Updated Review,” Drug Delivery and Translational Research 13, no. 9 (2023): 2239–2253.

[67] T. Kawasaki, F. Sugihara, K. Fukushima, et al., “Loss of FCHSD1 Leads to Amelioration of Chronic Obstructive Pulmonary Disease,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 26 (2021): e2019167118.

[68] D. M. Diks and H. E. Allen, “Correlation of Copper Distribution in a Freshwater-Sediment System to Bioavailability,” Bulletin of Environmental Contamination and Toxicology 30, no. 1 (1983): 37–43.

[69] K. Williams and J. Roman, “Studying Human Respiratory Disease in Animals – Role of Induced and Naturally Occurring Models,” Journal of Pathology 238, no. 2 (2015): 220–232.

[70] T. Hartung, “The (Misleading) Role of Animal Models in Drug Development,” Frontiers in Drug Discovery 4 (2024): 1355044.

[71] H. Frühwein and N. W. Paul, “Lost in Translation? Animal Research in the Era of Precision Medicine,” Journal of Translational Medicine 23, no. 1 (2025): 152.

[72] A. Mathur, P. Loskill, K. Shao, et al., “Human iPSC-Based Cardiac Microphysiological System for Drug Screening Applications,” Scientific Reports 5, no. 1 (2015): 8883.

[73] A. S. Morais, M. Mendes, M. A. Cordeiro, et al., “Organ-on-a-Chip: Ubi Sumus? Fundamentals and Design Aspects,” Pharmaceutics 16, no. 5 (2024): 615.

[74] E. Ergir, B. Bachmann, H. Redl, et al., “Small Force, Big Impact: Next Generation Organ-on-a-Chip Systems Incorporating Biomechanical Cues,” Frontiers in Physiology 9 (2018): 1417.

[75] J. Puschhof, C. Pleguezuelos-Manzano, and H. Clevers, “Organoids and Organs-on-Chips: Insights Into Human Gut-Microbe Interactions,” Cell Host & Microbe 29, no. 6 (2021): 867–878.

[76] R. Kane, “Patterning Proteins and Cells Using Soft Lithography,” Biomaterials 20, no. 23–24 (1999): 2363–2376.

[77] D. Huh, B. D. Matthews, A. Mammoto, et al., “Reconstituting Organ-Level Lung Functions on a Chip,” Science 328, no. 5986 (2010): 1662–1668.

[78] S. Deng, C. Li, J. Cao, et al., “Organ-on-a-Chip Meets Artificial Intelligence in Drug Evaluation,” Theranostics 13, no. 13 (2023): 4526–4558.

[79] D. Huh, D. C. Leslie, B. D. Matthews, et al., “A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice,” Science Translational Medicine 4 (2012): 159ra147.

[80] I. Raimondi, L. Izzo, M. Tunesi, et al., “Organ-On-A-Chip in Vitro Models of the Brain and the Blood-Brain Barrier and Their Value to Study the Microbiota-Gut-Brain Axis in Neurodegeneration,” Frontiers in Bioengineering and Biotechnology 7 (2020): 435.

[81] Y. S. Zhang, J. Aleman, A. Arneri, et al., “From Cardiac Tissue Engineering to Heart-on-a-Chip: Beating Challenges,” Biomedical Materials 10, no. 3 (2015): 034006.

[82] A. Marsano, C. Conficconi, M. Lemme, et al., “Beating Heart on a Chip: A Novel Microfluidic Platform to Generate Functional 3D Cardiac Microtissues,” Lab on a Chip 16, no. 3 (2016): 599–610.

[83] T. I. Maulana, C. Teufel, M. Cipriano, et al., “Breast Cancer-on-Chip for Patient-Specific Efficacy and Safety Testing of CAR-T Cells,” Cell Stem Cell 31, no. 7 (2024): 989–1002.e1009.

[84] S. Satta, S. J. Rockwood, K. Wang, et al., “Microfluidic Organ-Chips and Stem Cell Models in the Fight against COVID-19,” Circulation Research 132, no. 10 (2023): 1405–1424.

[85] F. Verdugo-Avello, J. K. Wychowaniec, C. A. Villacis-Aguirre, et al., “Bone Microphysiological Models for Biomedical Research,” Lab on a Chip 25, no. 5 (2025): 806–836.

[86] S. Bang, S. Lee, N. Choi, et al., “Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip,” Advanced Healthcare Materials 10, no. 12 (2021): e2002119.

[87] C. L. Clausen and T. Benfield, “Viral Pneumonia in Immunocompetent Adults,” Ugeskrift for Laeger 183, no. 18 (2021): V11200833.

[88] D. Kang, J. A. Park, W. Kim, et al., “All-Inkjet-Printed 3D Alveolar Barrier Model With Physiologically Relevant Microarchitecture,” Advanced Science 8 (2021): 2004990.

[89] S.-Y. Qin, Y.-J. Cheng, Q. Lei, et al., “Combinational Strategy for High-Performance Cancer Chemotherapy,” Biomaterials 171 (2018): 178–197.

[90] N. Wang, T. Ma, and B. Yu, “Targeting Epigenetic Regulators to Overcome Drug Resistance in Cancers,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 69.

[91] B. A. Hassell, G. Goyal, E. Lee, et al., “Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy in Vitro,” Cell Reports 21, no. 2 (2017): 508–516.

[92] Z. Xu, E. Li, Z. Guo, et al., “Design and Construction of a Multi-Organ Microfluidic Chip Mimicking the in Vivo Microenvironment of Lung Cancer Metastasis,” ACS Applied Materials & Interfaces 8, no. 39 (2016): 25840–25847.

[93] J. W. Mims, “Asthma: Definitions and Pathophysiology,” International Forum of Allergy & Rhinology 5, no. S1 (2015): S2–6.

[94] J. C. Nawroth, C. Lucchesi, D. Cheng, et al., “A Microengineered Airway Lung Chip Models Key Features of Viral-Induced Exacerbation of Asthma,” American Journal of Respiratory Cell and Molecular Biology 63, no. 5 (2020): 591–600.

[95] K. H. Benam, R. Novak, J. Nawroth, et al., “Matched-Comparative Modeling of Normal and Diseased Human Airway Responses Using a Microengineered Breathing Lung Chip,” Cell Systems 3, no. 5 (2016): 456–466.e454.

[96] S. A. Christenson, B. M. Smith, M. Bafadhel, et al., “Chronic Obstructive Pulmonary Disease,” Lancet 399, no. 10342 (2022): 2227–2242.

[97] C. Raherison and P. O. Girodet, “Epidemiology of COPD,” European Respiratory Review 18, no. 114 (2009): 213–221.

[98] P. J. Barnes, “Inflammatory Mechanisms in Patients With Chronic Obstructive Pulmonary Disease,” Journal of Allergy and Clinical Immunology 138, no. 1 (2016): 16–27.

[99] T. J. Bennet, A. Randhawa, J. Hua, et al., “Airway-On-A-Chip: Designs and Applications for Lung Repair and Disease,” Cells 10, no. 7 (2021): 1602.

[100] K. H. Benam, R. Villenave, C. Lucchesi, et al., “Small Airway-on-a-Chip Enables Analysis of Human Lung Inflammation and Drug Responses in Vitro,” Nature Methods 13, no. 2 (2015): 151–157.

[101] L. Richeldi, H. R. Collard, and M. G. Jones, “Idiopathic Pulmonary Fibrosis,” Lancet 389, no. 10082 (2017): 1941–1952.

[102] C. Mazio, L. S. Scognamiglio, R. Passariello, et al., “Easy-to-Build and Reusable Microfluidic Device for the Dynamic Culture of Human Bronchial Cystic Fibrosis Epithelia,” ACS Biomaterials Science & Engineering 9, no. 5 (2023): 2780–2792.

[103] R. Plebani, R. Potla, M. Soong, et al., “Modeling Pulmonary Cystic Fibrosis in a Human Lung Airway-on-a-Chip,” Journal of Cystic Fibrosis 21, no. 4 (2022): 606–615.

[104] X. Zhang, H. Liu, H. Cheng, et al., “In Vitro Biomimetic Models for respiratory Diseases: Progress in Lung Organoids and Lung-on-a-Chip,” Stem Cell Research & Therapy 16, no. 1 (2025): 415.

[105] P. Pound, “Are Animal Models Needed to Discover, Develop and Test Pharmaceutical Drugs for Humans in the 21st Century?,” Animals 10, no. 12 (2020): 2455.

[106] C. Ma, Y. Peng, H. Li, et al., “Organ-on-a-Chip: A New Paradigm for Drug Development,” Trends in Pharmacological Sciences 42, no. 2 (2021): 119–133.

[107] A. Tajeddin and N. Mustafaoglu, “Design and Fabrication of Organ-on-Chips: Promises and Challenges,” Micromachines 12, no. 12 (2021): 1443.

[108] L. Zheng, Y. Wang, Y. Zhang, et al., “Investigation of PM2.5-Induced Carcinogenic Effects Through Mediation of ErbB Family Based on DNA Methylation and Transcriptomics Analysis by a Lung-Mimicking Microfluidic Platform,” Ecotoxicology and Environmental Safety 248 (2022): 114318.

[109] M. C. Koyilot, P. Natarajan, C. R. Hunt, et al., “Breakthroughs and Applications of Organ-on-a-Chip Technology,” Cells 11, no. 11 (2022): 1828.

[110] X. Chen, Y. S. Zhang, X. Zhang, et al., “Organ-on-a-Chip Platforms for Accelerating the Evaluation of Nanomedicine,” Bioactive Materials 6, no. 4 (2021): 1012–1027.

[111] H. Azizgolshani, J. R. Coppeta, E. M. Vedula, et al., “High-Throughput Organ-on-Chip Platform With Integrated Programmable Fluid Flow and Real-Time Sensing for Complex Tissue Models in Drug Development Workflows,” Lab on a Chip 21, no. 8 (2021): 1454–1474.

[112] A. K. Marrone, F. A. Beland, and I. P. Pogribny, “The Role for microRNAs in Drug Toxicity and in Safety Assessment,” Expert Opinion on Drug Metabolism & Toxicology 11, no. 4 (2015): 601–611.

[113] J. Dingemanse and S. Appel-Dingemanse, “Integrated Pharmacokinetics and Pharmacodynamics in Drug Development,” Clinical Pharmacokinetics 46, no. 9 (2007): 713–737.

[114] J. H. Sung, C. Kam, and M. L. Shuler, “A Microfluidic Device for a Pharmacokinetic–Pharmacodynamic (PK-PD) Model on a Chip,” Lab on a Chip 10, no. 4 (2010): 446.

[115] A. M. B. Amorim, L. F. Piochi, A. T. Gaspar, et al., “Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction,” Chemical Research in Toxicology 37, no. 6 (2024): 827–849.

[116] E. W. Esch, A. Bahinski, and D. Huh, “Organs-on-Chips at the Frontiers of Drug Discovery,” Nature Reviews Drug Discovery 14, no. 4 (2015): 248–260.

[117] J. T. Atkins, G. C. George, K. Hess, et al., “Pre-clinical Animal Models Are Poor Predictors of human Toxicities in Phase 1 Oncology Clinical Trials,” British Journal of Cancer 123, no. 10 (2020): 1496–1501.

[118] X. Yang, K. Li, X. Zhang, et al., “Nanofiber Membrane Supported Lung-on-a-Chip Microdevice for Anti-Cancer Drug Testing,” Lab on a Chip 18, no. 3 (2018): 486–495.

[119] T. S. Frost, L. Jiang, and Y. Zohar, “Pharmacokinetic Analysis of Epithelial/Endothelial Cell Barriers in Microfluidic Bilayer Devices With an Air-Liquid Interface,” Micromachines 11, no. 5 (2020): 536.

[120] A. Jain, R. Barrile, A. D. van der Meer, et al., “Primary Human Lung Alveolus-on-a-Chip Model of Intravascular Thrombosis for Assessment of Therapeutics,” Clinical Pharmacology & Therapeutics 103, no. 2 (2017): 332–340.

[121] N. Sunildutt, P. Parihar, A. R. Chethikkattuveli Salih, et al., “Revolutionizing Drug Development: Harnessing the Potential of Organ-on-Chip Technology for Disease Modeling and Drug Discovery,” Frontiers in Pharmacology 14 (2023): 1139229.

[122] W.-H. Yuan, H.-C. Hsu, Y.-Y. Chen, et al., “Supplemental Breast Cancer-Screening Ultrasonography in Women With Dense Breasts: A Systematic Review and Meta-Analysis,” British Journal of Cancer 123, no. 4 (2020): 673–688.

[123] Y. Tohjima, P. K. Patra, Y. Niwa, et al., “Detection of Fossil-Fuel CO2 Plummet in China due to COVID-19 by Observation at Hateruma,” Scientific Reports 10, no. 1 (2020): 18688.

[124] A. F. Turgeon, D. A. Fergusson, L. Clayton, et al., “Haemoglobin Transfusion Threshold in Traumatic Brain Injury Optimisation (HEMOTION): A Multicentre, Randomised, Clinical Trial Protocol,” BMJ Open 12, no. 10 (2022): e067117.

[125] M. Alsharedi, R. Srivastava, and N. Elmsherghi, “Durvalumab for the Treatment of Urothelial Carcinoma,” Drugs of Today 53, no. 12 (2017): 647.

[126] A. Mullard, “Is the FDA's Plan to Phase out Animal Toxicity Testing Realistic?,” Nature Reviews Drug Discovery 24, no. 6 (2025): 413–414.

[127] S. G. Teixeira, P. Houeto, F. Gattacceca, et al., “National Reflection on Organs-on-Chip for Drug Development: New Regulatory Challenges,” Toxicology Letters 388 (2023): 1–12.

[128] X. He, X. Liu, F. Zuo, et al., “Artificial Intelligence-Based Multi-Omics Analysis Fuels Cancer Precision Medicine,” Seminars in Cancer Biology 88 (2023): 187–200.

[129] C. Chen, J. Wang, D. Pan, et al., “Applications of Multi-Omics Analysis in Human Diseases,” MedComm 4, no. 4 (2023): e315.

[130] M. K. Heavey, D. Durmusoglu, N. Crook, et al., “Discovery and Delivery Strategies for Engineered Live Biotherapeutic Products,” Trends in Biotechnology 40, no. 3 (2022): 354–369.

[131] J. M. Lee, H. M. Hammarén, M. M. Savitski, et al., “Control of Protein Stability by Post-Translational Modifications,” Nature Communications 14, no. 1 (2023): 201.

[132] B. C. Muthubharathi, T. Gowripriya, and K. Balamurugan, “Metabolomics: Small Molecules That Matter More,” Molecular Omics 17, no. 2 (2021): 210–229.

[133] A. Zhang, H. Sun, H. Xu, et al., “Cell Metabolomics,” OMICS: A Journal of Integrative Biology 17, no. 10 (2013): 495–501.

[134] M. R. Wilkins, J.-C. Sanchez, A. A. Gooley, et al., “Progress With Proteome Projects: Why all Proteins Expressed by a Genome Should be Identified and How To Do It,” Biotechnology and Genetic Engineering Reviews 13, no. 1 (1996): 19–50.

[135] Y. Yadi, S. Ziyi, H. Bin, et al., “Application of Proteomics in the Study of Toxicology and Toxic Markers of Traditional Chinese Medicines,” Biomedical Chromatography 39, no. 10 (2025): e70216.

[136] T. J. Garrett, T. D. P. Goralski, C. C. Jenkins, et al., “A Novel Approach to Interrogating the Effects of Chemical Warfare Agent Exposure Using Organ-on-a-Chip Technology and Multiomic Analysis,” PLoS ONE 18, no. 2 (2023): e0280883.

[137] D. J. Jung, T. H. Shin, M. Kim, et al., “A One-Stop Microfluidic-Based Lung Cancer Organoid Culture Platform for Testing Drug Sensitivity,” Lab on a Chip 19, no. 17 (2019): 2854–2865.

[138] Z. Li, X. Li, B. Feng, et al., “Combining a Lung Microfluidic Chip Exposure Model With Transcriptomic Analysis to Evaluate the Inflammation in BEAS-2B Cells Exposed to Cigarette Smoke,” Analytica Chimica Acta 1287 (2024): 342049.

[139] P. Wang, L. Jin, M. Zhang, et al., “Blood-Brain Barrier Injury and Neuroinflammation Induced by SARS-CoV-2 in a Lung-Brain Microphysiological System,” Nature Biomedical Engineering 8, no. 8 (2023): 1053–1068.

[140] L. Zheng, B. Wang, Y. Sun, et al., “An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs,” ACS Sensors 6, no. 3 (2021): 823–832.

[141] F. Yin, X. Zhang, L. Wang, et al., “HiPSC-Derived Multi-Organoids-on-Chip System for Safety Assessment of Antidepressant Drugs,” Lab on a Chip 21, no. 3 (2021): 571–581.

[142] Y. Man, R. R. Posey, H. Bai, et al., “Preclinical Assessment of Pan-influenza A Virus CRISPR RNA Therapeutics in a Human Lung Alveolus Chip,” Lab on a Chip 25, no. 20 (2025): 5240–5254.

[143] X. Wang, M. Cirit, J. S. Wishnok, et al., “Analysis of an Integrated Human Multiorgan Microphysiological System for Combined Tolcapone Metabolism and Brain Metabolomics,” Analytical Chemistry 91, no. 13 (2019): 8667–8675.

[144] R. Riahi, S. A. M. Shaegh, M. Ghaderi, et al., “Automated Microfluidic Platform of Bead-Based Electrochemical Immunosensor Integrated With Bioreactor for Continual Monitoring of Cell Secreted Biomarkers,” Scientific Reports 6, no. 1 (2016): 24598.

[145] E.-K. Min, C.-M. Lee, S.-R. Kim, et al., “Advanced Lung-on-a-Chip Technology: Mimicking the Complex Human Lung Microenvironment,” International Journal of Biological Sciences 21, no. 1 (2025): 17–39.

[146] S. Jalili-Firoozinezhad, F. S. Gazzaniga, E. L. Calamari, et al., “A Complex Human Gut Microbiome Cultured in an Anaerobic Intestine-on-a-Chip,” Nature Biomedical Engineering 3, no. 7 (2019): 520–531.

[147] X. Liu and J. W. Locasale, “Metabolomics: A Primer,” Trends in Biochemical Sciences 42, no. 4 (2017): 274–284.

[148] K. Ronaldson-Bouchard, D. Teles, K. Yeager, et al., “A Multi-Organ Chip With Matured Tissue Niches Linked by Vascular Flow,” Nature Biomedical Engineering 6, no. 4 (2022): 351–371.

[149] M. W. Toepke and D. J. Beebe, “PDMS Absorption of Small Molecules and Consequences in Microfluidic Applications,” Lab on a Chip 6, no. 12 (2006): 1484.

[150] J. E. Ekert, J. Deakyne, P. Pribul-Allen, et al., “Recommended Guidelines for Developing, Qualifying, and Implementing Complex in Vitro Models (CIVMs) for Drug Discovery,” SLAS Discovery 25, no. 10 (2020): 1174–1190.

[151] D. E. Ingber, “Human Organs-on-Chips for Disease Modelling, Drug Development and Personalized Medicine,” Nature Reviews Genetics 23, no. 8 (2022): 467–491.

[152] R. Novak, M. Ingram, S. Marquez, et al., “Robotic Fluidic Coupling and Interrogation of Multiple Vascularized Organ Chips,” Nature Biomedical Engineering 4, no. 4 (2020): 407–420.

[153] K. Ren, J. Zhou, and H. Wu, “Materials for Microfluidic Chip Fabrication,” Accounts of Chemical Research 46, no. 11 (2013): 2396–2406.

[154] L. A. Low, C. Mummery, B. R. Berridge, et al., “Organs-on-Chips: Into the next Decade,” Nature Reviews Drug Discovery 20, no. 5 (2020): 345–361.

[155] P. G. Miller and M. L. Shuler, “Design and Demonstration of a Pumpless 14 Compartment Microphysiological System,” Biotechnology and Bioengineering 113, no. 10 (2016): 2213–2227.

[156] Y. Wang, X. Chang, S. Deng, et al., “Functional Material Probes and Advanced Technologies in Organ-on-a-Chip Characterization,” Theranostics 16, no. 5 (2026): 2488–2516.

[157] J. Lim, C. Park, M. Kim, et al., “Advances in Single-Cell Omics and Multiomics for High-Resolution Molecular Profiling,” Experimental & Molecular Medicine 56, no. 3 (2024): 515–526.

[158] G. X. Y. Zheng, J. M. Terry, P. Belgrader, et al., “Massively Parallel Digital Transcriptional Profiling of Single Cells,” Nature Communications 8, no. 1 (2017): 14049.

[159] Q. Ruan, J. Yang, F. Zou, et al., “Single-Cell Digital Microfluidic Mass Spectrometry Platform for Efficient and Multiplex Genotyping of Circulating Tumor Cells,” Analytical Chemistry 94, no. 2 (2021): 1108–1117.

[160] Y. Zhu, P. D. Piehowski, R. Zhao, et al., “Nanodroplet Processing Platform for Deep and Quantitative Proteome Profiling of 10–100 Mammalian Cells,” Nature Communications 9, no. 1 (2018): 882.

[161] H. Hamzeiy, D. Ferretti, M. S. Robles, et al., “Perseus Plugin “Metis” for Metabolic-Pathway-Centered Quantitative Multi-Omics Data Analysis for Static and Time-Series Experimental Designs,” Cell Reports Methods 2, no. 4 (2022): 100198.

[162] H. Cui, C. Wang, H. Maan, et al., “scGPT: Toward Building a Foundation Model for Single-Cell Multi-Omics Using Generative AI,” Nature Methods 21, no. 8 (2024): 1470–1480.

[163] Q. Nie, Y. Kan, Y. Qi, et al., “Integration of Unpaired Single Cell Omics Data by Deep Transfer Graph Convolutional Network,” PLOS Computational Biology 21, no. 1 (2025): e1012625.

[164] R. Argelaguet, D. Arnol, D. Bredikhin, et al., “MOFA+: A Statistical Framework for Comprehensive Integration of Multi-Modal Single-Cell Data,” Genome Biology 21, no. 1 (2020): 111.

[165] S. Orchard, M. Ammari, B. Aranda, et al., “The MIntAct Project-IntAct as a Common Curation Platform for 11 Molecular Interaction Databases,” Nucleic Acids Research 42, no. D1 (2014): D358–D363.

[166] B. Liu, S. Wang, H. Ma, et al., “Heart-on-a-Chip: A Revolutionary Organ-on-Chip Platform for Cardiovascular Disease Modeling,” Journal of Translational Medicine 23, no. 1 (2025): 132.

[167] A. Herland, B. M. Maoz, D. Das, et al., “Quantitative Prediction of Human Pharmacokinetic Responses to Drugs via Fluidically Coupled Vascularized Organ Chips,” Nature Biomedical Engineering 4, no. 4 (2020): 421–436.

[168] M. Ballerini, S. Galiè, P. Tyagi, et al., “A Gut-on-a-Chip Incorporating Human Faecal Samples and Peristalsis Predicts Responses to Immune Checkpoint Inhibitors for Melanoma,” Nature Biomedical Engineering 9, no. 6 (2025): 967–984.

[169] M. Morsink, N. Willemen, J. Leijten, et al., “Immune Organs and Immune Cells on a Chip: An Overview of Biomedical Applications,” Micromachines 11, no. 9 (2020): 849.

[170] H. Zhao, L. Wu, G. Yan, et al., “Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 263.

[171] F. Weinberg, R. P. Dickson, D. Nagrath, et al., “The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?,” Cancers 13, no. 1 (2020): 13.

[172] X. Yu, Q. Zheng, Y. He, et al., “Associations of Gut Microbiota and Fatty Metabolism with Immune Thrombocytopenia,” Frontiers in Medicine 9 (2022): 810612.

[173] M. Coates, M. J. Lee, D. Norton, et al., “The Skin and Intestinal Microbiota and Their Specific Innate Immune Systems,” Frontiers in Immunology 10 (2019): 2950.

[174] M. Kasendra, A. Tovaglieri, A. Sontheimer-Phelps, et al., “Development of a Primary Human Small Intestine-on-a-Chip Using Biopsy-Derived Organoids,” Scientific Reports 8, no. 1 (2018): 2871.

[175] W. Shin, A. Wu, M. W. Massidda, et al., “A Robust Longitudinal Co-Culture of Obligate Anaerobic Gut Microbiome with Human Intestinal Epithelium in an Anoxic-Oxic Interface-on-a-Chip,” Frontiers in Bioengineering and Biotechnology 7 (2019): 13.

[176] H. Wang, X. Li, P. Shi, et al., “Establishment and Evaluation of on-Chip Intestinal Barrier Biosystems Based on Microfluidic Techniques,” Materials Today Bio 26 (2024): 101079.

[177] J. Deng, Y. Qu, T. Liu, et al., “Recent Organ-on-a-Chip Advances Toward Drug Toxicity Testing,” Microphysiological Systems 1 (2018): 1–1.

[178] M. Trapecar, C. Communal, J. Velazquez, et al., “Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids,” Cell Systems 10, no. 3 (2020): 223–239.

[179] C. Oleaga, A. Riu, S. Rothemund, et al., “Investigation of the Effect of Hepatic Metabolism on Off-Target Cardiotoxicity in a Multi-Organ Human-on-a-Chip System,” Biomaterials 182 (2018): 176–190.

[180] S. Fuchs, S. Johansson, A. Ø. Tjell, et al., “In-Line Analysis of Organ-on-Chip Systems With Sensors: Integration, Fabrication, Challenges, and Potential,” ACS Biomaterials Science & Engineering 7, no. 7 (2021): 2926–2948.

[181] C. D. Edington, W. L. K. Chen, E. Geishecker, et al., “Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies,” Scientific Reports 8, no. 1 (2018): 4530.

[182] Y. Cong, X. Han, Y. Wang, et al., “Drug Toxicity Evaluation Based on Organ-on-a-Chip Technology: A Review,” Micromachines 11, no. 4 (2020): 381.

[183] D. Bavli, S. Prill, and E. Ezra, “Real-Time Monitoring of Metabolic Function in Liver-on-Chip Microdevices Tracks the Dynamics of Mitochondrial Dysfunction,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 16 (2016): E2231–E2240.

[184] G. Palla, D. S. Fischer, A. Regev, et al., “Spatial Components of Molecular Tissue Biology,” Nature Biotechnology 40, no. 3 (2022): 308–318.

[185] D. Bressan, G. Battistoni, and G. J. Hannon, “The Dawn of Spatial Omics,” Science 381, no. 6657 (2023): eabq4964.

[186] A. Rao, D. Barkley, G. S. França, et al., “Exploring Tissue Architecture Using Spatial Transcriptomics,” Nature 596, no. 7871 (2021): 211–220.

[187] Y. Goltsev, N. Samusik, J. Kennedy-Darling, et al., “Deep Profiling of Mouse Splenic Architecture With CODEX Multiplexed Imaging,” Cell 174, no. 4 (2018): 968–981.

[188] L. Keren, M. Bosse, D. Marquez, et al., “A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging,” Cell 174, no. 6 (2018): 1373–1387.

[189] C. Xia, J. Fan, and G. Emanuel, “Spatial Transcriptome Profiling by MERFISH Reveals Subcellular RNA Compartmentalization and Cell Cycle-Dependent Gene Expression,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 39 (2019): 19490–19499.

[190] A. L. Ji, A. J. Rubin, K. Thrane, et al., “Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma,” Cell 182, no. 2 (2020): 497–514.

[191] S. M. Lewis, M.-L. Asselin-Labat, Q. Nguyen, et al., “Spatial Omics and Multiplexed Imaging to Explore Cancer Biology,” Nature Methods 18, no. 9 (2021): 997–1012.

[192] M. V. Hunter, R. Moncada, J. M. Weiss, et al., “Spatially Resolved Transcriptomics Reveals the Architecture of the Tumor-Microenvironment Interface,” Nature Communications 12, no. 1 (2021): 6278.

[193] B. S. Carvalho and G. Rustici, “The Challenges of Delivering Bioinformatics Training in the Analysis of High-Throughput Data,” Briefings in Bioinformatics 14, no. 5 (2013): 538–547.

[194] F. Sartori, F. Codicè, I. Caranzano, et al., “A Comprehensive Review of Deep Learning Applications With Multi-Omics Data in Cancer Research,” Genes 16, no. 6 (2025): 648.

[195] M. Zitnik, M. Agrawal, and J. Leskovec, “Modeling Polypharmacy Side Effects With Graph Convolutional Networks,” Bioinformatics 34, no. 13 (2018): i457–i466.

[196] R. Lopez, J. Regier, M. B. Cole, et al., “Deep Generative Modeling for Single-Cell Transcriptomics,” Nature Methods 15, no. 12 (2018): 1053–1058.

[197] G. Schneider, “Automating Drug Discovery,” Nature Reviews Drug Discovery 17, no. 2 (2017): 97–113.

[198] F. T. Musuamba, I. Skottheim Rusten, R. Lesage, et al., “Scientific and Regulatory Evaluation of Mechanistic in Silico Drug and Disease Models in Drug Development: Building Model Credibility,” CPT: Pharmacometrics & Systems Pharmacology 10, no. 8 (2021): 804–825.

[199] T. Eissing, “A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks,” Frontiers in Physiology 2 (2011): 4.

[200] K. Ronaldson-Bouchard and G. Vunjak-Novakovic, “Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development,” Cell Stem Cell 22, no. 3 (2018): 310–324.

[201] C. O. Aloba, “Organ-on-a-Chip in Regenerative Medicine: Advancing Tissue Repair and Personalized Therapies,” International Journal of Research Publication and Reviews 6, no. 1 (2025): 2427–2446.

[202] G. A. Ramírez-González, C. Consumi-Tubito, E. Vargas-Méndez, et al., “Advancing Organ-on-a-Chip Systems: The Role of Scaffold Materials and Coatings in Engineering Cell Microenvironment,” Polymers 17, no. 9 (2025): 1263.

[203] D. N. Tavakol, S. Fleischer, and G. Vunjak-Novakovic, “Harnessing Organs-on-a-Chip to Model Tissue Regeneration,” Cell Stem Cell 28, no. 6 (2021): 993–1015.

[204] G. Goyal, C. Belgur, and D. E. Ingber, “Human Organ Chips for Regenerative Pharmacology,” Pharmacology Research & Perspectives 12, no. 1 (2023): e01159.

[205] U. Upadhyay, S. Kolla, S. Maredupaka, et al., “Development of an Alginate–Chitosan Biopolymer Composite With dECM Bioink Additive for Organ-on-a-Chip Articular Cartilage,” Scientific Reports 14, no. 1 (2024): 11765.

[206] D. A. Brenner, “Alternatives to Animal Testing to Assess MASH Drugs and Hepatotoxicity,” Hepatology 81, no. 1 (2025): 304–311.

[207] L. Ewart, K. Fabre, A. Chakilam, et al., “Navigating Tissue Chips From Development to Dissemination: A Pharmaceutical Industry Perspective,” Experimental Biology and Medicine 242, no. 16 (2017): 1579–1585.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.